Share Price and Basic Stock Data
Last Updated: December 4, 2025, 2:27 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Chemiesynth (Vapi) Ltd operates within the organic chemicals sector, primarily focusing on niche products. The company has had a tumultuous revenue journey, with sales peaking at ₹30.18 Cr in FY 2022 before declining to ₹20.94 Cr in FY 2023. However, the trailing twelve months (TTM) revenue stands at ₹20.00 Cr, suggesting a slight recovery. Quarterly sales data reveals fluctuations, with a notable spike to ₹7.12 Cr in December 2022, but subsequent quarters have shown a downturn, with the most recent quarter reporting sales of ₹4.37 Cr. This volatility indicates that Chemiesynth is still struggling to establish a consistent revenue stream. The cyclical nature of the chemicals industry, combined with operational challenges, may be contributing factors to these fluctuations.
Profitability and Efficiency Metrics
The profitability metrics for Chemiesynth reflect an ongoing battle with operational efficiency. The company reported a negative net profit of ₹0.32 Cr, a stark contrast to the ₹2.72 Cr profit recorded in FY 2022. Operating profit margins (OPM) have seen significant volatility, peaking at 31.35% in September 2023 before falling to 12.13% in the latest reporting period. This inconsistency suggests that while Chemiesynth can achieve strong margins intermittently, sustaining them remains a challenge. Additionally, the return on equity (ROE) stands at a meager 0.99%, indicating that shareholders are not seeing substantial returns on their investments. The interest coverage ratio of 2.75x does provide some comfort, suggesting that the company can meet its interest obligations, but the overall profitability context is concerning.
Balance Sheet Strength and Financial Ratios
Chemiesynth’s balance sheet reveals a mixed picture. The company has total borrowings of ₹15.02 Cr against reserves of ₹7.91 Cr, leading to a debt-to-equity ratio of 1.37x. This level of leverage could be seen as a risk, especially in an industry where margins can be tight. On the positive side, the price-to-book value ratio is at 0.95x, suggesting that the stock is trading close to its book value, which might attract value investors. Additionally, the current ratio of 0.46x indicates potential liquidity issues, as it falls below the ideal threshold of 1. This raises concerns about the company’s short-term financial stability. Overall, while the balance sheet has some strengths, the high debt levels and liquidity ratios signal caution.
Shareholding Pattern and Investor Confidence
The shareholding structure of Chemiesynth is relatively stable, with promoters holding 62.35% of the equity. This substantial stake suggests a level of confidence from the founding members in the company’s long-term potential. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may raise flags for some retail investors, as it indicates a lack of broader market endorsement. The public holding stands at 37.66%, with a total of 524 shareholders, which is modest. This concentration of ownership could lead to volatility if there are shifts in promoter sentiment or strategic direction. Overall, while the promoter backing is a strength, the limited institutional interest may dampen broader investor confidence.
Outlook, Risks, and Final Insight
Looking ahead, Chemiesynth faces a dual-edged sword of opportunities and risks. The chemicals sector has potential for growth, particularly with global shifts towards sustainable and specialty chemicals. However, the company’s inconsistent revenue streams and profitability metrics highlight significant operational challenges that need to be addressed. Risks also stem from its high leverage and liquidity concerns, which could become critical if market conditions worsen or if sales do not stabilize. Investors should consider these factors carefully; while the low price-to-book ratio may signal a buying opportunity for value seekers, the underlying operational inefficiencies and financial risks warrant a cautious approach. In a volatile market, this stock may appeal to those with a higher risk tolerance, but the path to recovery appears fraught with challenges that could impact future performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujchem Distillers India Ltd | 102 Cr. | 285 | 456/255 | 237 | 392 | 0.04 % | 0.21 % | 0.09 % | 1.00 |
| Elantas Beck India Ltd | 7,536 Cr. | 9,506 | 14,250/8,150 | 54.6 | 1,177 | 0.08 % | 23.0 % | 17.4 % | 10.0 |
| Crestchem Ltd | 35.3 Cr. | 118 | 329/109 | 17.5 | 26.9 | 0.85 % | 59.9 % | 44.1 % | 10.0 |
| Chemiesynth (Vapi) Ltd | 11.6 Cr. | 37.6 | 37.6/35.8 | 32.8 | 0.00 % | 3.10 % | 0.99 % | 10.0 | |
| ARCL Organics Ltd | 308 Cr. | 385 | 435/163 | 17.1 | 108 | 0.00 % | 20.4 % | 16.8 % | 10.0 |
| Industry Average | 4,325.15 Cr | 1,556.36 | 65.40 | 334.84 | 0.41% | 14.71% | 10.69% | 7.56 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.54 | 4.43 | 7.12 | 4.85 | 4.39 | 4.37 | 3.22 | 4.45 | 2.85 | 5.47 | 3.88 | 6.68 |
| Expenses | 4.76 | 3.94 | 5.78 | 3.89 | 4.48 | 3.00 | 3.31 | 4.10 | 2.66 | 4.51 | 3.65 | 5.87 |
| Operating Profit | -0.22 | 0.49 | 1.34 | 0.96 | -0.09 | 1.37 | -0.09 | 0.35 | 0.19 | 0.96 | 0.23 | 0.81 |
| OPM % | -4.85% | 11.06% | 18.82% | 19.79% | -2.05% | 31.35% | -2.80% | 7.87% | 6.67% | 17.55% | 5.93% | 12.13% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest | 0.11 | 0.16 | 0.15 | 0.16 | 0.12 | 0.21 | 0.11 | 0.26 | 0.09 | 0.17 | 0.34 | 0.20 |
| Depreciation | 0.27 | 0.27 | 0.30 | 0.33 | 0.30 | 0.32 | 0.32 | 0.36 | 0.34 | 0.38 | 0.36 | 0.33 |
| Profit before tax | -0.60 | 0.06 | 0.89 | 0.47 | -0.51 | 0.84 | -0.52 | -0.26 | -0.24 | 0.41 | -0.47 | 0.29 |
| Tax % | 0.00% | 0.00% | 5.62% | 44.68% | 0.00% | 0.00% | 0.00% | -23.08% | 0.00% | 0.00% | 0.00% | 34.48% |
| Net Profit | -0.61 | 0.06 | 0.84 | 0.26 | -0.51 | 0.85 | -0.52 | -0.20 | -0.24 | 0.42 | -0.47 | 0.19 |
| EPS in Rs | -1.99 | 0.20 | 2.74 | 0.85 | -1.66 | 2.77 | -1.69 | -0.65 | -0.78 | 1.37 | -1.53 | 0.62 |
Last Updated: May 31, 2025, 6:32 am
Below is a detailed analysis of the quarterly data for Chemiesynth (Vapi) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 6.68 Cr.. The value appears strong and on an upward trend. It has increased from 3.88 Cr. (Dec 2024) to 6.68 Cr., marking an increase of 2.80 Cr..
- For Expenses, as of Mar 2025, the value is 5.87 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.65 Cr. (Dec 2024) to 5.87 Cr., marking an increase of 2.22 Cr..
- For Operating Profit, as of Mar 2025, the value is 0.81 Cr.. The value appears strong and on an upward trend. It has increased from 0.23 Cr. (Dec 2024) to 0.81 Cr., marking an increase of 0.58 Cr..
- For OPM %, as of Mar 2025, the value is 12.13%. The value appears strong and on an upward trend. It has increased from 5.93% (Dec 2024) to 12.13%, marking an increase of 6.20%.
- For Other Income, as of Mar 2025, the value is 0.01 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Dec 2024) to 0.01 Cr., marking an increase of 0.01 Cr..
- For Interest, as of Mar 2025, the value is 0.20 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.34 Cr. (Dec 2024) to 0.20 Cr., marking a decrease of 0.14 Cr..
- For Depreciation, as of Mar 2025, the value is 0.33 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.36 Cr. (Dec 2024) to 0.33 Cr., marking a decrease of 0.03 Cr..
- For Profit before tax, as of Mar 2025, the value is 0.29 Cr.. The value appears strong and on an upward trend. It has increased from -0.47 Cr. (Dec 2024) to 0.29 Cr., marking an increase of 0.76 Cr..
- For Tax %, as of Mar 2025, the value is 34.48%. The value appears to be increasing, which may not be favorable. It has increased from 0.00% (Dec 2024) to 34.48%, marking an increase of 34.48%.
- For Net Profit, as of Mar 2025, the value is 0.19 Cr.. The value appears strong and on an upward trend. It has increased from -0.47 Cr. (Dec 2024) to 0.19 Cr., marking an increase of 0.66 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.62. The value appears strong and on an upward trend. It has increased from -1.53 (Dec 2024) to 0.62, marking an increase of 2.15.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9.63 | 11.13 | 5.12 | 3.09 | 13.32 | 11.20 | 14.56 | 19.90 | 30.18 | 20.94 | 16.43 | 18.89 | 20.00 |
| Expenses | 9.10 | 11.55 | 5.26 | 3.17 | 12.67 | 9.26 | 12.27 | 14.32 | 25.71 | 18.37 | 14.88 | 16.68 | 17.82 |
| Operating Profit | 0.53 | -0.42 | -0.14 | -0.08 | 0.65 | 1.94 | 2.29 | 5.58 | 4.47 | 2.57 | 1.55 | 2.21 | 2.18 |
| OPM % | 5.50% | -3.77% | -2.73% | -2.59% | 4.88% | 17.32% | 15.73% | 28.04% | 14.81% | 12.27% | 9.43% | 11.70% | 10.90% |
| Other Income | 0.13 | 0.02 | 0.03 | 0.27 | 0.46 | 0.06 | 0.12 | 0.02 | 0.94 | 0.00 | 0.01 | 0.01 | 0.01 |
| Interest | 0.30 | 0.29 | 0.23 | 0.19 | 0.19 | 0.09 | 0.28 | 0.48 | 0.50 | 0.59 | 0.71 | 0.83 | 0.96 |
| Depreciation | 0.25 | 0.28 | 0.20 | 0.18 | 0.52 | 0.46 | 0.55 | 0.78 | 1.05 | 1.17 | 1.30 | 1.40 | 1.46 |
| Profit before tax | 0.11 | -0.97 | -0.54 | -0.18 | 0.40 | 1.45 | 1.58 | 4.34 | 3.86 | 0.81 | -0.45 | -0.01 | -0.23 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 19.31% | 17.09% | 17.74% | 29.79% | 32.10% | -13.33% | 1,000.00% | |
| Net Profit | 0.11 | -0.97 | -0.54 | -0.18 | 0.39 | 1.17 | 1.31 | 3.56 | 2.72 | 0.56 | -0.39 | -0.11 | -0.32 |
| EPS in Rs | 0.36 | -3.16 | -1.76 | -0.59 | 1.27 | 3.81 | 4.27 | 11.60 | 8.86 | 1.82 | -1.27 | -0.36 | -1.04 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -981.82% | 44.33% | 66.67% | 316.67% | 200.00% | 11.97% | 171.76% | -23.60% | -79.41% | -169.64% | 71.79% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1026.15% | 22.34% | 250.00% | -116.67% | -188.03% | 159.79% | -195.35% | -55.82% | -90.23% | 241.44% |
Chemiesynth (Vapi) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 5% |
| 3 Years: | -14% |
| TTM: | 34% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -191% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 11% |
| 3 Years: | 0% |
| Last Year: | -1% |
Last Updated: September 5, 2025, 2:56 pm
Balance Sheet
Last Updated: December 10, 2025, 4:03 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 |
| Reserves | 0.70 | -0.28 | -0.82 | -1.05 | -0.66 | 0.52 | 1.83 | 5.39 | 8.10 | 8.66 | 8.27 | 7.91 | 7.01 |
| Borrowings | 6.46 | 6.70 | 8.17 | 8.02 | 8.01 | 7.69 | 9.73 | 10.86 | 11.60 | 13.63 | 15.54 | 15.02 | 15.21 |
| Other Liabilities | 3.00 | 2.74 | 1.27 | 1.58 | 1.48 | 3.59 | 3.18 | 7.55 | 6.86 | 5.65 | 4.49 | 6.19 | 7.27 |
| Total Liabilities | 13.23 | 12.23 | 11.69 | 11.62 | 11.90 | 14.87 | 17.81 | 26.87 | 29.63 | 31.01 | 31.37 | 32.19 | 32.56 |
| Fixed Assets | 10.41 | 10.09 | 9.98 | 9.71 | 9.62 | 10.69 | 12.31 | 20.39 | 22.38 | 24.51 | 25.08 | 25.83 | 27.38 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 1.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 2.82 | 2.14 | 1.71 | 1.91 | 2.28 | 3.94 | 4.16 | 6.48 | 7.25 | 6.50 | 6.29 | 6.36 | 5.18 |
| Total Assets | 13.23 | 12.23 | 11.69 | 11.62 | 11.90 | 14.87 | 17.81 | 26.87 | 29.63 | 31.01 | 31.37 | 32.19 | 32.56 |
Below is a detailed analysis of the balance sheet data for Chemiesynth (Vapi) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 3.07 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.07 Cr..
- For Reserves, as of Sep 2025, the value is 7.01 Cr.. The value appears to be declining and may need further review. It has decreased from 7.91 Cr. (Mar 2025) to 7.01 Cr., marking a decrease of 0.90 Cr..
- For Borrowings, as of Sep 2025, the value is 15.21 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 15.02 Cr. (Mar 2025) to 15.21 Cr., marking an increase of 0.19 Cr..
- For Other Liabilities, as of Sep 2025, the value is 7.27 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.19 Cr. (Mar 2025) to 7.27 Cr., marking an increase of 1.08 Cr..
- For Total Liabilities, as of Sep 2025, the value is 32.56 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 32.19 Cr. (Mar 2025) to 32.56 Cr., marking an increase of 0.37 Cr..
- For Fixed Assets, as of Sep 2025, the value is 27.38 Cr.. The value appears strong and on an upward trend. It has increased from 25.83 Cr. (Mar 2025) to 27.38 Cr., marking an increase of 1.55 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 5.18 Cr.. The value appears to be declining and may need further review. It has decreased from 6.36 Cr. (Mar 2025) to 5.18 Cr., marking a decrease of 1.18 Cr..
- For Total Assets, as of Sep 2025, the value is 32.56 Cr.. The value appears strong and on an upward trend. It has increased from 32.19 Cr. (Mar 2025) to 32.56 Cr., marking an increase of 0.37 Cr..
However, the Borrowings (15.21 Cr.) are higher than the Reserves (7.01 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.93 | -7.12 | -8.31 | -8.10 | -7.36 | -5.75 | -7.44 | -5.28 | -7.13 | -11.06 | -13.99 | -12.81 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 12.51 | 26.89 | 31.37 | 24.81 | 27.13 | 55.08 | 39.86 | 67.86 | 41.60 | 47.24 | 47.10 | 55.07 |
| Inventory Days | 126.69 | 44.60 | 136.35 | 580.41 | 16.18 | 231.23 | 217.06 | 165.17 | 80.99 | 200.09 | 386.19 | 167.61 |
| Days Payable | 156.86 | 126.75 | 159.43 | 741.97 | 43.60 | 605.79 | 366.21 | 695.35 | 159.36 | 200.78 | 111.85 | 201.64 |
| Cash Conversion Cycle | -17.66 | -55.26 | 8.29 | -136.75 | -0.29 | -319.48 | -109.29 | -462.31 | -36.77 | 46.55 | 321.44 | 21.04 |
| Working Capital Days | -48.89 | -53.78 | -47.76 | -103.95 | -9.04 | -28.68 | -60.92 | -65.85 | -49.83 | -65.89 | -105.08 | -122.12 |
| ROCE % | 3.04% | -6.90% | -3.21% | -2.44% | 5.28% | 13.73% | 13.89% | 28.39% | 16.35% | 5.82% | 1.00% | 3.10% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.35 | -1.26 | 1.81 | 8.85 | 11.60 |
| Diluted EPS (Rs.) | -0.35 | -1.26 | 1.81 | 8.85 | 11.60 |
| Cash EPS (Rs.) | 4.22 | 2.97 | 5.61 | 12.28 | 14.14 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 35.77 | 36.94 | 38.20 | 36.39 | 27.55 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 35.77 | 36.94 | 38.20 | 36.39 | 27.55 |
| Revenue From Operations / Share (Rs.) | 61.52 | 53.53 | 68.21 | 98.32 | 64.81 |
| PBDIT / Share (Rs.) | 7.14 | 5.04 | 8.34 | 14.58 | 18.03 |
| PBIT / Share (Rs.) | 2.57 | 0.80 | 4.54 | 11.15 | 15.49 |
| PBT / Share (Rs.) | -0.02 | -1.47 | 2.65 | 12.57 | 14.12 |
| Net Profit / Share (Rs.) | -0.34 | -1.26 | 1.81 | 8.85 | 11.60 |
| PBDIT Margin (%) | 11.60 | 9.41 | 12.22 | 14.83 | 27.82 |
| PBIT Margin (%) | 4.18 | 1.50 | 6.65 | 11.33 | 23.90 |
| PBT Margin (%) | -0.04 | -2.74 | 3.88 | 12.78 | 21.78 |
| Net Profit Margin (%) | -0.56 | -2.36 | 2.65 | 8.99 | 17.89 |
| Return on Networth / Equity (%) | -0.96 | -3.42 | 4.73 | 24.30 | 42.11 |
| Return on Capital Employeed (%) | 3.87 | 1.16 | 6.50 | 17.22 | 26.86 |
| Return On Assets (%) | -0.32 | -1.23 | 1.79 | 9.16 | 13.25 |
| Long Term Debt / Equity (X) | 0.73 | 0.75 | 0.71 | 0.67 | 1.07 |
| Total Debt / Equity (X) | 1.37 | 1.37 | 1.16 | 1.04 | 1.28 |
| Asset Turnover Ratio (%) | 0.59 | 0.52 | 0.69 | 1.07 | 0.89 |
| Current Ratio (X) | 0.46 | 0.53 | 0.60 | 0.68 | 0.65 |
| Quick Ratio (X) | 0.30 | 0.21 | 0.30 | 0.45 | 0.49 |
| Inventory Turnover Ratio (X) | 7.20 | 1.11 | 2.48 | 5.82 | 2.02 |
| Interest Coverage Ratio (X) | 2.75 | 2.22 | 4.41 | 9.33 | 13.16 |
| Interest Coverage Ratio (Post Tax) (X) | 0.86 | 0.44 | 1.96 | 4.75 | 9.46 |
| Enterprise Value (Cr.) | 25.47 | 23.72 | 19.75 | 16.16 | 0.00 |
| EV / Net Operating Revenue (X) | 1.35 | 1.44 | 0.94 | 0.53 | 0.00 |
| EV / EBITDA (X) | 11.62 | 15.33 | 7.71 | 3.61 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.55 | 0.50 | 0.29 | 0.18 | 0.00 |
| Price / BV (X) | 0.95 | 0.72 | 0.52 | 0.49 | 0.00 |
| Price / Net Operating Revenue (X) | 0.55 | 0.50 | 0.29 | 0.18 | 0.00 |
| EarningsYield | -0.01 | -0.04 | 0.09 | 0.48 | 0.00 |
After reviewing the key financial ratios for Chemiesynth (Vapi) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -0.35. This value is below the healthy minimum of 5. It has increased from -1.26 (Mar 24) to -0.35, marking an increase of 0.91.
- For Diluted EPS (Rs.), as of Mar 25, the value is -0.35. This value is below the healthy minimum of 5. It has increased from -1.26 (Mar 24) to -0.35, marking an increase of 0.91.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.22. This value is within the healthy range. It has increased from 2.97 (Mar 24) to 4.22, marking an increase of 1.25.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 35.77. It has decreased from 36.94 (Mar 24) to 35.77, marking a decrease of 1.17.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 35.77. It has decreased from 36.94 (Mar 24) to 35.77, marking a decrease of 1.17.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 61.52. It has increased from 53.53 (Mar 24) to 61.52, marking an increase of 7.99.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 7.14. This value is within the healthy range. It has increased from 5.04 (Mar 24) to 7.14, marking an increase of 2.10.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.57. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 2.57, marking an increase of 1.77.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.02. This value is below the healthy minimum of 0. It has increased from -1.47 (Mar 24) to -0.02, marking an increase of 1.45.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.34. This value is below the healthy minimum of 2. It has increased from -1.26 (Mar 24) to -0.34, marking an increase of 0.92.
- For PBDIT Margin (%), as of Mar 25, the value is 11.60. This value is within the healthy range. It has increased from 9.41 (Mar 24) to 11.60, marking an increase of 2.19.
- For PBIT Margin (%), as of Mar 25, the value is 4.18. This value is below the healthy minimum of 10. It has increased from 1.50 (Mar 24) to 4.18, marking an increase of 2.68.
- For PBT Margin (%), as of Mar 25, the value is -0.04. This value is below the healthy minimum of 10. It has increased from -2.74 (Mar 24) to -0.04, marking an increase of 2.70.
- For Net Profit Margin (%), as of Mar 25, the value is -0.56. This value is below the healthy minimum of 5. It has increased from -2.36 (Mar 24) to -0.56, marking an increase of 1.80.
- For Return on Networth / Equity (%), as of Mar 25, the value is -0.96. This value is below the healthy minimum of 15. It has increased from -3.42 (Mar 24) to -0.96, marking an increase of 2.46.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.87. This value is below the healthy minimum of 10. It has increased from 1.16 (Mar 24) to 3.87, marking an increase of 2.71.
- For Return On Assets (%), as of Mar 25, the value is -0.32. This value is below the healthy minimum of 5. It has increased from -1.23 (Mar 24) to -0.32, marking an increase of 0.91.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.73. This value is within the healthy range. It has decreased from 0.75 (Mar 24) to 0.73, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.37. This value exceeds the healthy maximum of 1. There is no change compared to the previous period (Mar 24) which recorded 1.37.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.59. It has increased from 0.52 (Mar 24) to 0.59, marking an increase of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1.5. It has decreased from 0.53 (Mar 24) to 0.46, marking a decrease of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 0.30. This value is below the healthy minimum of 1. It has increased from 0.21 (Mar 24) to 0.30, marking an increase of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.20. This value is within the healthy range. It has increased from 1.11 (Mar 24) to 7.20, marking an increase of 6.09.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.75. This value is below the healthy minimum of 3. It has increased from 2.22 (Mar 24) to 2.75, marking an increase of 0.53.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 3. It has increased from 0.44 (Mar 24) to 0.86, marking an increase of 0.42.
- For Enterprise Value (Cr.), as of Mar 25, the value is 25.47. It has increased from 23.72 (Mar 24) to 25.47, marking an increase of 1.75.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.35. This value is within the healthy range. It has decreased from 1.44 (Mar 24) to 1.35, marking a decrease of 0.09.
- For EV / EBITDA (X), as of Mar 25, the value is 11.62. This value is within the healthy range. It has decreased from 15.33 (Mar 24) to 11.62, marking a decrease of 3.71.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.55. This value is below the healthy minimum of 1. It has increased from 0.50 (Mar 24) to 0.55, marking an increase of 0.05.
- For Price / BV (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1. It has increased from 0.72 (Mar 24) to 0.95, marking an increase of 0.23.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.55. This value is below the healthy minimum of 1. It has increased from 0.50 (Mar 24) to 0.55, marking an increase of 0.05.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has increased from -0.04 (Mar 24) to -0.01, marking an increase of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chemiesynth (Vapi) Ltd:
- Net Profit Margin: -0.56%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.87% (Industry Average ROCE: 14.71%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -0.96% (Industry Average ROE: 10.69%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.86
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.3
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 65.4)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.37
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -0.56%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Organic - Others | Plot No 27, GIDC, Phase-1 Vapi, Valsad District Gujarat 396195 | compliance@chemiesynth.com www.chemiesynth.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sandip Satishbhai Zaveri | Managing Director |
| Mr. Satish Bhogilal Zaveri | Non Exe.Non Ind.Director |
| Mr. Rushabh Suresh Mehta | Non Exe.Non Ind.Director |
| Mr. Pramod Gopaldas Gujarathi | Independent Director |
| Mrs. Jigna Prajapati | Independent Woman Director |
FAQ
What is the intrinsic value of Chemiesynth (Vapi) Ltd?
Chemiesynth (Vapi) Ltd's intrinsic value (as of 13 December 2025) is 3.97 which is 89.44% lower the current market price of 37.60, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 11.6 Cr. market cap, FY2025-2026 high/low of 37.6/35.8, reserves of ₹7.01 Cr, and liabilities of 32.56 Cr.
What is the Market Cap of Chemiesynth (Vapi) Ltd?
The Market Cap of Chemiesynth (Vapi) Ltd is 11.6 Cr..
What is the current Stock Price of Chemiesynth (Vapi) Ltd as on 13 December 2025?
The current stock price of Chemiesynth (Vapi) Ltd as on 13 December 2025 is 37.6.
What is the High / Low of Chemiesynth (Vapi) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Chemiesynth (Vapi) Ltd stocks is 37.6/35.8.
What is the Stock P/E of Chemiesynth (Vapi) Ltd?
The Stock P/E of Chemiesynth (Vapi) Ltd is .
What is the Book Value of Chemiesynth (Vapi) Ltd?
The Book Value of Chemiesynth (Vapi) Ltd is 32.8.
What is the Dividend Yield of Chemiesynth (Vapi) Ltd?
The Dividend Yield of Chemiesynth (Vapi) Ltd is 0.00 %.
What is the ROCE of Chemiesynth (Vapi) Ltd?
The ROCE of Chemiesynth (Vapi) Ltd is 3.10 %.
What is the ROE of Chemiesynth (Vapi) Ltd?
The ROE of Chemiesynth (Vapi) Ltd is 0.99 %.
What is the Face Value of Chemiesynth (Vapi) Ltd?
The Face Value of Chemiesynth (Vapi) Ltd is 10.0.